DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed an agreement with Eli Lilly and Company (NYSE: LLY) to manage the company’s clinical data management business outside the United States. The agreement, which spans more than three dozen countries, excluding the United States and Japan, will help to transform Lilly’s research and development organisation as they seek to drive productivity, gain speed to market and lower drug development costs.
